MTSR

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ken GriffinCitadel Advisors $-5.4M ExitQ4 2025 $5M -- $70.50
Chuck RoyceRoyce & Associates $-5.4M ExitQ4 2025 $5M -- $70.50
Andreas HalvorsenViking Global $-46.0M ExitQ3 2025 $46M -- $70.50
Ken GriffinCitadel Advisors $-2.2M TrimQ3 2025 $2M -- $70.50
Chuck RoyceRoyce & Associates $-4.1M TrimQ3 2025 $4M -- $70.50
Ken GriffinCitadel Advisors $6.3M AddQ2 2025 $6M -- $70.50

Insider Trades

Name	Value	Action	Price	Last Price
Fmr LLC10 Percent Owner, Other: See Remark 1 $12k193 shares SellNov 3, 2025 $61.23 $70.50
Fmr LLC10 Percent Owner, Other: See Remark 1 $9.6k268 shares SellSep 2, 2025 $36.00 $70.50

News

proactiveinvestors.co.ukIP Group shares jump 9% as Metsera deal drives return to growthproactiveinvestors.co.ukMar 17

Trade MTSR

About Metsera, Inc.

Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.

CEO: Christopher Whitten Bernard
IPO Date: Jan 31, 2025

Market Data

Open: $70.74
High: $70.76
Low: $70.13
Volume: 27.9M
52W High: $83.86
52W Low: $12.30

Valuation

Market Cap: $7.4B
Enterprise Value: $7B

Financials

Free Cash Flow: -$99.8M
Revenue: $0
Net Income: -$209.1M
Cash: $352.4M
Debt: $9.8M

Events

EarningsMar 25

EPS est. -0.54